安罗替尼同步放疗一线治疗中晚期老年食管癌临床观察  

Clinical observation on anlotinib combined with concurrent radiotherapy in the treatment of elderly patients with advanced esophageal cancer

作　　者：庞慧[1] 李志平[1] PANG Hui;LI Zhiping(Department of Oncology,the Second People’s Hospital of Jiaozuo,Jiaozuo 454001,China)

机构地区：[1]焦作市第二人民医院肿瘤内科,河南焦作454001

出　　处：《肿瘤基础与临床》2022年第5期377-379,共3页journal of basic and clinical oncology

基　　金：河南省科技攻关计划项目(2018020995)。

摘　　要：目的 探讨安罗替尼同步放疗一线治疗中晚期老年食管癌患者的疗效和不良反应。方法 选取57例中晚期老年食管癌患者,随机分为对照组(28例)和治疗组(29例)。对照组仅行单纯放疗,治疗组从放疗开始起同步口服安罗替尼。比较2组患者近期疗效、生活质量和不良反应。结果 治疗组总有效率为82.8%,高于对照组的53.6%,差异有统计学意义(χ~2=13.873,P<0.001)。治疗组和对照组治疗后生活质量评分[(88.17±5.25)、(61.74±4.29)分]均较治疗前[(51.27±4.16)、(50.26±3.84)分]有提高(t=10.267,P=0.010;t=1.079,P=0.759),而且治疗组明显高于对照组,差异有统计学意义(t=10.267,P=0.010)。安罗替尼最主要不良反应有食欲不振、乏力、高血压、蛋白尿等,放疗常见不良反应有骨髓抑制、消化道反应、放射性食管炎等,所有不良反应经对症处理后恢复良好,未发现影响治疗顺利进行的不良反应。结论 安罗替尼联合放疗可提高老年食管癌患者的疗效,改善患者生活质量,并不增加不良反应,值得临床应用。Objective To explore the efficacy and adverse reactions of anlotinib combined with concurrent radiotherapy in the first-line treatment of elderly patients with advanced esophageal cancer. Methods The 57 elderly patients with advanced esophageal cancer were randomly divided into two groups. The control group(n=28) were treated with radiotherapy alone, the treat group(n=29) were treated with oral anlotinib from radiotherapy starting date. The treat effect, quality of life and adverse reactions were compared between the two groups. Results The total effective rate in the treatment group(82.8%) was higher than that in the control group(53.6%), the difference was statistically significant(χ~2=13.873,P<0.001). The quality of life scores after treatment in the treatment group [(88.17±5.25) scores] and in the control group [(61.74±4.29) scores] were significantly higher than those before treatment [(51.27±4.16) and(50.26±3.84)scores;t=10.267,P=0.010;t=1.079,P=0.759], and the KPS score was higher than that in the control group after treatment( t=10.267,P=0.010). The main adverse reactions of arotinib included anorexia, asthenia, hypertension, proteinuria, etc. Common adverse reactions of radiotherapy included bone marrow suppression, digestive tract reaction, radiation esophagitis. All the adverse reactions recovered well after symptomatic treatment, and no adverse reactions affecting the smooth progress of treatment were found.Conclusion Anlotinib combined with concurrent radiotherapy can improve the curative effect and the quality of life in the first-line treatment of elderly patients with advanced esophageal cancer, and have the better safety. It worthy of clinical application.

关 键 词：安罗替尼 老年患者 中晚期食管癌 放疗 

分 类 号：R735.1[医药卫生—肿瘤]